The impact of neoadjuvant chemotherapy on skeletal muscle depletion and preoperative sarcopenia in patients with resectable colorectal liver metastases

HPB

Volumn 19, Issue 4, 2017, Pages 331-337

  Eriksson, Sam ^a   Nilsson, Jan H ^a   Strandberg Holka, Peter ^a   Eberhard, Jakob ^a   Keussen, Inger ^a   Sturesson, Christian ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BODY HEIGHT; CANCER ADJUVANT THERAPY; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; OVERALL SURVIVAL; PREOPERATIVE PERIOD; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SARCOPENIA; THIRD LUMBAR VERTEBRA; ADJUVANT CHEMOTHERAPY; CHEMICALLY INDUCED; COLORECTAL TUMOR; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; DRUG EFFECTS; KAPLAN MEIER METHOD; LIVER TUMOR; METASTASIS RESECTION; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECONDARY; SKELETAL MUSCLE; TIME FACTOR; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

AGED; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; METASTASECTOMY; MIDDLE AGED; MUSCLE, SKELETAL; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SARCOPENIA; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 85009487417     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1016/j.hpb.2016.11.009     Document Type: Article

References (26)

1. 1 Torre, L.A., Siegel, R.L., Ward, E.M., Jemal, A., Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomark Prev 25 (2016), 16–27.
2. 2 Manfredi, S., Lepage, C., Hatem, C., Coatmeur, O., Faivre, J., Bouvier, A.M., Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244 (2006), 254–259.
3. 3 Pawlik, T.M., Choti, M.A., Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 11 (2007), 1057–1077.
4. 4 Pawlik, T.M., Schulick, R.D., Choti, M.A., Expanding criteria for resectability of colorectal liver metastases. Oncologist 13 (2008), 51–64.
5. 5 Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G.J., Schlag, P.M., Rougier, P., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008), 1007–1016.
6. 6 Makary, M.A., Segev, D.L., Pronovost, P.J., Syin, D., Bandeen-Roche, K., Patel, P., et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 210 (2010), 901–908.
7. 7 Janssen, I., Heymsfield, S.B., Ross, R., Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 50 (2002), 889–896.
8. 8 Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31 (2013), 1539–1547.
9. 9 Levolger, S., van Vugt, J.L., de Bruin, R.W., Ijzermans, J.N., Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies. Br J Surg 102 (2015), 1448–1458.
10. 10 Prado, C.M., Lieffers, J.R., McCargar, L.J., Reiman, T., Sawyer, M.B., Martin, L., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9 (2008), 629–635.
11. 11 van Vledder, M.G., Levolger, S., Ayez, N., Verhoef, C., Tran, T.C., Ijzermans, J.N., Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 99 (2012), 550–557.
12. 12 Peng, P.D., van Vledder, M.G., Tsai, S., de Jong, M.C., Makary, M., Ng, J., et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB 13 (2011), 439–446.
13. 13 Cooper, A.B., Slack, R., Fogelman, D., Holmes, H.M., Petzel, M., Parker, N., et al. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann Surg Oncol 22 (2015), 2416–2423.
14. 14 Awad, S., Tan, B.H., Cui, H., Bhalla, A., Fearon, K.C., Parsons, S.L., et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 31 (2012), 74–77.
15. 15 Miyamoto, Y., Baba, Y., Sakamoto, Y., Ohuchi, M., Tokunaga, R., Kurashige, J., et al. Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS One, 10, 2015, e0129742.
16. 16 Dindo, D., Demartines, N., Clavien, P.A., Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240 (2004), 205–213.
17. 17 Mourtzakis, M., Prado, C.M., Lieffers, J.R., Reiman, T., McCargar, L.J., Baracos, V.E., A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33 (2008), 997–1006.
18. 18 Yip, C., Goh, V., Davies, A., Gossage, J., Mitchell-Hay, R., Hynes, O., et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol 24 (2014), 998–1005.
19. 19 Voron, T., Tselikas, L., Pietrasz, D., Pigneur, F., Laurent, A., Compagnon, P., et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg 261 (2015), 1173–1183.
20. 20 Lodewick, T.M., van Nijnatten, T.J., van Dam, R.M., van Mierlo, K., Dello, S.A., Neumann, U.P., et al. Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases?. HPB 17 (2015), 438–446.
21. 21 Dello, S.A., Lodewick, T.M., van Dam, R.M., Reisinger, K.W., van den Broek, M.A., von Meyenfeldt, M.F., et al. Sarcopenia negatively affects preoperative total functional liver volume in patients undergoing liver resection. HPB 15 (2013), 165–169.
22. 22 Cherin, P., Voronska, E., Fraoucene, N., de Jaeger, C., Prevalence of sarcopenia among healthy ambulatory subjects: the sarcopenia begins from 45 years. Aging Clin Exp Res 26 (2014), 137–146.
23. 23 Ryan, A.M., Power, D.G., Daly, L., Cushen, S.J., Ni Bhuachalla, E., Prado, C.M., Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc, 2016, 1–13.
24. 24 Binay Safer, V., Safer, U., Kaplan, M., Terekeci, H., Top, C., Commentary on “Preoperative sarcopenia negatively impacts postoperative outcomes following major hepatectomy with extrahepatic bile duct resection”. World J Surg 39 (2015), 2370–2371.
25. 25 Baumgartner, R.N., Koehler, K.M., Gallagher, D., Romero, L., Heymsfield, S.B., Ross, R.R., et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147 (1998), 755–763.
26. 26 Dunne, D.F., Jack, S., Jones, R.P., Jones, L., Lythgoe, D.T., Malik, H.Z., et al. Randomized clinical trial of prehabilitation before planned liver resection. Br J Surg 103 (2016), 504–512.